US Patent

US11389467 — Topical compositions

Method of Use · Assigned to Bausch Health Ireland Ltd · Expires 2040-12-28 · 15y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a topical gel formulation for treating inflammatory skin conditions, including acne, with specific concentrations of clindamycin phosphate, benzoyl peroxide, and adapalene.

USPTO Abstract

The disclosure provides a topical gel formulation comprising 1-1.5 wt. % clindamycin phosphate, 2.5-3.5 wt. % benzoyl peroxide, and 0.1-0.2 wt. % adapalene, in combination with a gelling agent, a polyhydric alcohol, and water, useful in treating inflammatory skin conditions, including acne, together with methods of making and using the same.

Drugs covered by this patent

Differin (ADAPALENE) · Galderma Labs Lp

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3713`	—	Differin

Patent Metadata

Patent number: US11389467
Jurisdiction: US
Classification: Method of Use
Expires: 2040-12-28
Drug substance claim: No
Drug product claim: Yes
Assignee: Bausch Health Ireland Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.